Structured evidence table for Pectin Gut Microbiome Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Pectin Gut Microbiome Randomized Trial | Background Imidazole propionate (ImP), a microbial metabolite of histidine, may impair glucose metabolism, but its relevance to coronary heart disease (CHD) risk and potential diet-microbiota regulations remain unclear. | 4 | Liang X (2026) | Circulating imidazole propionate and coronary heart disease risk: interplay between histidine intake, fiber, and gut microbiome. |
| Pectin Gut Microbiome Randomized Trial | We aimed to examine prospective associations of plasma ImP levels and histidine intake with CHD risk, to identify ImP-predicting gut microbes, and to investigate diet-microbiome interactions influencing ImP levels. | 4 | Liang X (2026) | Circulating imidazole propionate and coronary heart disease risk: interplay between histidine intake, fiber, and gut microbiome. |
| Pectin Gut Microbiome Randomized Trial | Methods Associations of ImP and histidine with CHD risk were evaluated using Cox models in 7,432 participants from Nurses' Health Study (NHS), NHSII, and Health Professionals Follow-up Study. | 4 | Liang X (2026) | Circulating imidazole propionate and coronary heart disease risk: interplay between histidine intake, fiber, and gut microbiome. |
Source documents